Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China flag China · Delayed Price · Currency is CNY
10.49
-0.41 (-3.76%)
Nov 13, 2026, 3:00 PM CST

SHA:603439 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,6361,7022,1441,6341,201938.84
Other Revenue
0.860.860.550.510.330.13
1,6371,7032,1441,6351,201938.97
Revenue Growth
-5.70%-20.59%31.16%36.10%27.94%48.99%
Cost of Revenue
471.93519.33652.98437.99339.52277.07
Gross Profit
1,1651,1841,4911,197861.8661.89
Selling, General & Admin
909.09948.31,089879.21618.01492.75
Research & Development
17.5827.9146.530.6117.867.68
Other Operating Expenses
18.126.8117.3116.611.018.56
Operating Expenses
952.86997.451,163929.77657.18509.98
Operating Income
212.07186.06328.34267.22204.62151.92
Interest Expense
-17.73-11.07-14.61-4.13-5.24-8.34
Interest & Investment Income
2.713.965.860.1317.5625.81
Other Non Operating Income (Expenses)
-6.49-0.05-0.371.89-0.21-0.09
EBT Excluding Unusual Items
190.56178.89319.16325.1216.74169.29
Impairment of Goodwill
-121.98-121.98---0.08-
Gain (Loss) on Sale of Investments
0.44-2.620.15--0.09-
Gain (Loss) on Sale of Assets
0.11-0.12-0.170.59-0.09-0.15
Asset Writedown
-1.05-0.03-0.57-0.05-0.1-0.01
Other Unusual Items
11.913.626.478.386.187.51
Pretax Income
79.9867.77325.03334.02222.56176.65
Income Tax Expense
2719.6145.1939.1530.6228.05
Earnings From Continuing Operations
52.9948.15279.84294.87191.94148.6
Minority Interest in Earnings
-0.14-1.9-5.81-2.179.353.68
Net Income
52.8446.25274.03292.7201.28152.28
Net Income to Common
52.8446.25274.03292.7201.28152.28
Net Income Growth
-67.11%-83.12%-6.38%45.42%32.18%62.08%
Shares Outstanding (Basic)
415420409412411412
Shares Outstanding (Diluted)
415420409412411412
Shares Change
3.30%2.81%-0.79%0.36%-0.19%5.14%
EPS (Basic)
0.130.110.670.710.490.37
EPS (Diluted)
0.130.110.670.710.490.37
EPS Growth
-68.16%-83.58%-5.63%44.90%32.43%54.17%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
180.8138.7461.87167.97173.38128.96
Free Cash Flow Per Share
0.430.330.150.410.420.31
Dividend Per Share
0.0600.0600.3400.2000.100-
Dividend Growth
-82.35%-82.35%70.00%100.00%-60.00%-
Gross Margin
71.17%69.50%69.55%73.21%71.74%70.49%
Operating Margin
12.96%10.93%15.31%16.34%17.03%16.18%
Profit Margin
3.23%2.72%12.78%17.90%16.75%16.22%
Free Cash Flow Margin
11.05%8.15%2.89%10.27%14.43%13.73%
EBITDA
283.32258.84403.16303.64220.44163.09
EBITDA Margin
17.31%15.20%18.80%18.57%18.35%17.37%
D&A For EBITDA
71.2572.7874.8236.4215.8211.17
EBIT
212.07186.06328.34267.22204.62151.92
EBIT Margin
12.96%10.93%15.31%16.34%17.03%16.18%
Effective Tax Rate
33.75%28.94%13.90%11.72%13.76%15.88%
Revenue as Reported
1,6371,7032,1441,6351,201938.97
Advertising Expenses
-0.211.471.782.290.01